A systematic review and meta-analysis of shugan jieyu capsule combined with escitalopram in the treatment of senile depression.

Researchers conducted a systematic review examining whether combining a traditional Chinese herbal medicine called Shugan Jieyu Capsule with the antidepressant escitalopram works better than medication alone for treating depression in older adults. The study analyzed eight randomized controlled trials involving 765 elderly patients with depression. The researchers looked at depression and anxiety scores, laboratory markers including serotonin levels, overall effectiveness, and side effects. The results showed that patients receiving the combination treatment experienced significantly greater improvements in depression scores and anxiety levels compared to those taking escitalopram alone. The combined treatment also increased serotonin levels, a brain chemical linked to mood regulation, and showed a 4.25 times higher overall effectiveness rate. Importantly, the combination therapy actually resulted in fewer adverse reactions than medication alone, suggesting it is well-tolerated. Treatment duration ranged from 6 to 12 weeks in the studies reviewed. While these findings are promising, it's important to note that this review focused specifically on a Chinese herbal formula rather than acupuncture itself. However, both approaches stem from Traditional Chinese Medicine principles and are often used together in clinical practice. For older adults struggling with depression, this research suggests that integrating certain herbal therapies with conventional antidepressants may enhance treatment outcomes while reducing side effects. If you're considering Traditional Chinese Medicine approaches including herbal therapy or acupuncture for depression, consult with a qualified, licensed acupuncturist or TCM practitioner experienced in treating geriatric patients.

This systematic review and meta-analysis evaluated Shugan Jieyu Capsule combined with escitalopram for senile depression. Eight RCTs comprising 765 patients were analyzed using GRADE methodology. Treatment duration ranged from 6-12 weeks. Results demonstrated significant improvements favoring combination therapy: total effective rate OR=4.25 (95%CI: 2.53-7.14, P<0.00001); HAMD score reduction SMD=-1.26 (95%CI: -1.45 to -1.08, P<0.00001); HAMA score reduction SMD=-0.82 (95%CI: -1.05 to -0.59, P<0.00001); and increased serum 5-HT levels MD=31.92 (95%CI: 28.34-35.50, P<0.00001). Notably, the combination therapy showed lower adverse reaction incidence OR=0.62 (95%CI: 0.42-0.92, P=0.02). Clinical implications suggest that integrating Shugan Jieyu Capsule with SSRIs may enhance therapeutic outcomes in geriatric depression while improving safety profiles. This supports a complementary approach combining TCM herbal formulations with conventional pharmacotherapy for this population.